phentermine has been researched along with liraglutide in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (68.97) | 24.3611 |
| 2020's | 9 (31.03) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J | 1 |
| Nakazato, M; Ueno, H | 1 |
| Aldhoon-Hainerová, I; Hainer, V | 1 |
| Hainer, V | 1 |
| Fujioka, K | 1 |
| Bragg, R; Crannage, E | 1 |
| Megyeri, J; Nuffer, W; Trujillo, JM | 1 |
| Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z | 1 |
| Braverman-Panza, J; Fujioka, K | 1 |
| Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH | 1 |
| Curry, SA | 1 |
| Gadde, KM; Pritham Raj, Y | 1 |
| Dixon, J; Lee, PC | 1 |
| Golden, A | 1 |
| Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG | 1 |
| Aronne, LJ; Chukir, T; Saunders, KH; Shukla, AP | 1 |
| Nadolsky, KZ | 1 |
| Andrew, CA; Aronne, LJ; Saunders, KH; Shukla, AP | 1 |
| Buch-Rasmussen, AS; Cowley, MA; Grove, KL; Kelly, LE; Koegler, FH; Pryor, JT; Simonds, SE | 1 |
| Alamuddin, N; Berkowitz, RI; Chao, AM; Gruber, K; Leonard, S; Tronieri, JS; Wadden, TA; Walsh, OA | 1 |
| Brown, SA; Izzy, M; Watt, KD | 1 |
| Lee, SY; Tak, YJ | 1 |
| Aronne, LJ; Redmond, IP; Shukla, AP | 1 |
| Kaur, N; Levin, A; Mainoo, NK; Perez, A | 1 |
| Germanidis, GS; Giouleme, O; Goulas, A; Goulis, DG; Polyzos, SA | 1 |
| Nolan, BJ; Proietto, J; Sumithran, P | 1 |
| Hill, A; Levi, J; Venter, F; Wang, J | 1 |
| Aziz, Z; Bellows, BK; Hur, C; Kelly, AS; Lim, F; Tan, SX; Woo Baidal, JA | 1 |
| Mital, S; Nguyen, HV | 1 |
17 review(s) available for phentermine and liraglutide
| Article | Year |
|---|---|
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss | 2012 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2014 |
Tolerability and safety of the new anti-obesity medications.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2014 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2015 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2016 |
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss | 2016 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain | 2017 |
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
Topics: Anti-Obesity Agents; Benzazepines; Clinical Trials as Topic; Fructose; Humans; Life Style; Liraglutide; Obesity; Phentermine; Topiramate; Weight Loss | 2017 |
Current pharmacotherapies for obesity: A practical perspective.
Topics: Adult; Anti-Obesity Agents; Benzazepines; Female; Humans; Lactones; Liraglutide; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Risk Reduction Behavior; United States | 2017 |
Pharmacotherapy for obesity: What you need to know.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine | 2017 |
Pharmacotherapy for obesity in individuals with type 2 diabetes.
Topics: Anti-Obesity Agents; Benzazepines; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Compounding; Humans; Lactones; Liraglutide; Obesity; Orlistat; Phentermine; Weight Loss | 2018 |
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.
Topics: Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Liraglutide; Obesity; Orlistat; Phentermine; Weight Loss | 2019 |
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical | 2021 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2021 |
Use of Weight Loss Medications in Patients after Bariatric Surgery.
Topics: Anti-Obesity Agents; Bariatric Surgery; Humans; Liraglutide; Obesity; Phentermine; Postoperative Period; Topiramate; Weight Gain; Weight Loss | 2021 |
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.
Topics: Anti-Obesity Agents; Humans; Liraglutide; Non-alcoholic Fatty Liver Disease; Obesity; Orlistat; Phentermine; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
1 trial(s) available for phentermine and liraglutide
| Article | Year |
|---|---|
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hunger; Liraglutide; Male; Middle Aged; Obesity; Phentermine; Pilot Projects; Treatment Outcome; Weight Loss | 2019 |
11 other study(ies) available for phentermine and liraglutide
| Article | Year |
|---|---|
Review of pharmacotherapy options for the management of obesity.
Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States | 2016 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss | 2016 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss | 2017 |
Pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Drug Therapy; Drug Therapy, Combination; Fructose; Humans; Incretins; Lactones; Liraglutide; Obesity; Orlistat; Phentermine; Topiramate | 2017 |
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.
Topics: Alcohol Deterrents; Appetite Depressants; Benzazepines; Cohort Studies; Drug Therapy; Humans; Incretins; Liraglutide; Military Personnel; Naltrexone; Obesity; Phentermine; Retrospective Studies | 2018 |
Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.
Topics: Animals; Anti-Obesity Agents; Blood Pressure; Body Weight; Drug Therapy, Combination; Heart Rate; Liraglutide; Male; Mice; Obesity; Phentermine; Treatment Outcome; Weight Loss | 2019 |
Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Nutrition Surveys; Obesity; Orlistat; Phentermine; Prevalence; Topiramate; United States; Weight Loss | 2022 |
Intensive management of obesity in people with Prader-Willi syndrome.
Topics: Child; Humans; Liraglutide; Obesity; Phentermine; Prader-Willi Syndrome; Retrospective Studies; Topiramate; Weight Loss | 2022 |
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate | 2023 |
Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
Topics: Adolescent; Cost-Benefit Analysis; Female; Humans; Liraglutide; Male; Pediatric Obesity; Phentermine; Topiramate; United States | 2023 |
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
Topics: Adolescent; Anti-Obesity Agents; Child; Cost-Benefit Analysis; Female; Humans; Liraglutide; Male; Obesity; Obesity, Morbid; Orlistat; Phentermine; Topiramate | 2023 |